

Calcium phosphate coated core-shell protein nanocarriers: robust stability, controlled release and enhanced anticancer activity for curcumin delivery

by Wu, Q., Gao, H., Vriesekoop, F., Liu, Z., He, J. and Liang, H.

Copyright, publisher and additional Information: This is the author accepted manuscript. The final published version (version of record) is available online via Elsevier.

This version is made available under the CC-BY-ND-NC licence:
<https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode>

Please refer to any applicable terms of use of the publisher

DOI: <https://doi.org/10.1016/j.msec.2020.111094>



Highlights

- NaCas@CaP nanodelivery system has nano-size and core-shell structure.
- The mechanism of encapsulation was characterized and analyzed.
- The stability of the encapsulated Cur was significantly improved.
- The pH-responsive release around the cancer cell was achieved.
- The encapsulated Cur existed better cellular anti-oxidant and anti-cancer ability.

1 **Calcium Phosphate Coated Core-Shell Protein**
2 **Nanocarriers: Robust Stability, Controlled Release**
3 **and Enhanced Anticancer Activity for Curcumin**
4 **Delivery**

5

6 Qiao Wu,^a Huiling Gao,^a Frank Vriesekoop,^c Zexun Liu,^a Jie He,^a Hao Liang^{*a, b}

7 ^aState Key Laboratory of Chemical Resource Engineering, Beijing University of
8 Chemical Technology, Beijing100029, P.R. China

9 ^bQinhuangdao Bohai Biological Research Institute of Beijing University of Chemical
10 Technology, Qinhuangdao 066000, China

11 ^cDepartment of Food Technology and Innovation, Harper Adams University,
12 Newport TF10 8NB, Shropshire, United Kingdom

13 Corresponding Author

14 * E-mail: lianghao@rmail.buct.edu.cn

15

16 **ABSTRACT:** Composite protein and inorganic nanodelivery systems can realise a
17 pH-responsive release and effectively improve the stability and anti-cancer
18 proliferative activity of hydrophobic molecules. In this study, a novel core-shell

19 structure of NaCas (Sodium Caseinate)@CaP (Calcium Phosphate) as a nanodelivery
20 system with NaCas as the core for increasing solubility and CaP as the shell for
21 enhanced stability was built. By using Cur (Curcumin) as a model bioactive molecule,
22 (Cur@NaCas)@CaP nanoparticles (NPs) demonstrated a uniform size distribution of
23 150-200 nm with a distinct nano-composite structure. After exposure to 80 °C for 2 h,
24 the NaCas@CaP loaded Cur still retained 80% stability while under the same
25 conditions only 12 % of free Cur remained intact. UV-light stability was remarkably
26 enhanced 8.56 fold by the protection of the core-shell structure. More importantly,
27 pH-responsive release was achieved owing to the CaP surface coating. The
28 encapsulated Cur by NaCas@CaP NPs exhibited an enhanced cellular anti-oxidant
29 activity (CAA) based on MGC-803 cell monolayer models. The confocal laser-
30 scanning microscopy (CLSM) images and cancer-cell-proliferation assay illustrated
31 that (Cur@NaCas)@CaP NPs showed significantly improvements of cellular uptake
32 and anti-cancer activity against A549 cancer cells than free Cur. These novel core-
33 shell NaCas@CaP NPs are very promising for intensifying the stability and
34 bioactivity of hydrophobic compounds in drug delivery and cancer treatment.

35

36 **Key words:** Nanodelivery, Sodium caseinate, Calcium phosphate, Curcumin, Anti-
37 oxidant, Anti-cancer

38

39 **1.Introduction**

40 Natural self-assembled delivery systems are nanodelivery systems formed by the
41 self-assembly of natural biomaterials with nanostructures.[1, 2] These biomaterials
42 can spontaneously form regular shapes, such as spheres, cylinders, lamellae, etc., by
43 relatively weak non-covalent interactions at concentrations well above their critical
44 micelle concentration.[3-5] These systems are mainly used to encapsulate, protect and
45 transport functional active substances because of their enhanced permeability and
46 retention effect.[6, 7] The enhanced permeability and retention effect refers to the
47 notion that certain macromolecules and nanoparticles accumulate inside tumor tissues
48 at greater concentrations compared to non-tumor tissues.[8] Compared with
49 traditional embedding technologies, natural self-assembled delivery systems have
50 size-related effects, due to the relatively random nature of the self-assembly process
51 which results in a heterogeneous range of surfaces and sized particles. Furthermore,
52 natural self-assembled delivery systems also have different in vivo distribution
53 specificity with regards to the targeted delivery of drugs and nutritional
54 compounds.[9, 10] Moreover, biodegradable self-assembled delivery systems improve
55 the bioavailability of guest molecules, and can achieve a controlled and sustained
56 release, and facilitate targeted delivery of bioactive compounds.[11] Due to their
57 biodegradability, natural self-assembled delivery systems pose minimal cytotoxicity,
58 are renewable and have an abundant availability, a high drug binding capacity, and a
59 significant uptake by target cells, protein-based delivery systems, including zein,[11]
60 soy protein isolate,[12] sodium caseinate[13] and ferritins,[14] have received
61 increasing attention as natural self-assembled delivery systems.


62 Sodium caseinates (NaCas) is a widely used food additive derived from milk. With
63 distinct hydrophobic and hydrophilic domains, NaCas can self-assemble into a stable
64 micellar structure in aqueous solution, especially when its concentration is higher than
65 the its critical micelle concentration.[13] Due to its excellent biocompatibility and
66 biodegradability, and limited immunogenicity, NaCas is regularly employed as a
67 unique natural self-assembled nanodelivery material in biological applications.[15]
68 NaCas has been used to enhance the solubility, stability and bioavailability of
69 otherwise insoluble natural compounds, especially those with considerable biological
70 activity, such as some vitamins and their precursors, [16-18] and antioxidants.[19]

71 Although the deployment of NaCas is a strategic improvement in the delivery of
72 otherwise recalcitrantly soluble bioactive molecules, the long-term stability of NaCas
73 nanoparticles (NPs) remains a major obstacle for their successful applications as
74 delivery vehicles. The structural integrity of NaCas is readily compromised as a
75 consequence of changes in pH, ionic strength, water activity, temperature or
76 pressure,[20] which causes an imbalance between hydrophobic and electrostatic
77 interactions.[21, 22] Various strategies for improving the stability of NaCas
78 nanostructures are emerging. Organic materials such as pectin,[23] chitosan,[24]
79 alginates,[25] and combinations thereof [26] have been used to stabilize NaCas NPs.
80 However, even these nanocarriers still fall short of providing sufficient
81 physicochemical stability and often require complicated assembly processes.[27, 28]
82 Therefore, a stable nanoscale NaCas system with a simple assembly method for its
83 synthesis is urgently needed for the delivery of sensitive molecules.

84 Hybridization of organic and inorganic carriers can confer nanomaterials with new
85 stability related properties not normally associated with the individual carriers.[29,
86 30] Calcium phosphate (CaP) NPs have good adsorption capacity and pH-responsive
87 release characterization for both proteins and drugs.[31-33] CaP NPs can deliver
88 diagnostic and therapeutic agents with minimal toxicity for the detection and
89 treatment of various diseases including cancer.[34]In order to improve the stability of
90 NaCas particles, we chose CaP to provide a secondary coating and as such address the
91 premature release from compounds encapsulated by NaCas.[13] We constructed
92 hybrid NaCas-CaP NPs (NaCas@CaP NPs) with a stable core-shell structure by
93 means of a simple, one-pot method under mild conditions using curcumin (Cur), a
94 natural anti-cancer biomolecule, as a model guest molecule (**Scheme 1**). Cur was
95 encapsulated into the core of NaCas micellar particles by hydrophobic interactions
96 during the self-assembly process of dissociated NaCas, yielding Cur@NaCas NPs.
97 The Cur@NaCas surface was simultaneously coated with CaP as a stable shell. The
98 formation and conformation of the encapsulated-core-and-shell NPs were
99 characterized by various means. The stability and *in vitro* releasing of
100 (Cur@NaCas)@CaP NPs at physiological pH and the pH encountered in cancer cells
101 were examined. In addition, the cellular uptake ability, the cellular anti-oxidant
102 activity and *in vitro* cell proliferation assay of the inclusion complexes were tested
103 and compared with free Cur. Our results indicated that the NaCas@CaP NPs with
104 high efficiency and stability are a novel nanoplatform for cancer therapy and free

105 radical scavenging *in vivo*. Furthermore, the NPs have universality for hydrophobic
106 sensitive molecules, which make these NPs a promising drug delivery system.

107



108

109 **Scheme 1** Schematic mechanism of encapsulation and cell-uptake of NaCas@CaP
110 loaded Cur.

111

112 2 Material and methods

113 2.1 Materials and Cell Culture

114 Curcumin (Cur, 98%), sodium caseinate (NaCas) were purchased from Macklin
115 Biochemical Co., Ltd, (Shanghai, China). 2,2-azobis (2-amidinopropane)
116 dihydrochloride (ABAP), 2,7-dichlorodi-hydrofluorescein diacetate (DCFH-DA), and
117 Propidium Iodide (PI) were obtained from Sigma-Aldrich, (St Louis, MO, USA). Cell
118 Counting Kit-8 (CCK-8) was obtained from Dojindo Laboratories (Tokyo, Japan). All
119 other chemicals (analytical grade) were purchased from Beijing Chemical Works
120 (Beijing, China), and were applied without further purification. Human gastric cancer
121 cells (MGC803) and human alveolar basal epithelial cancer cells (A549 cells) were
122 obtained from the Cell Resource Center, Peking Union Medical College (Beijing,

123 China), and cultured with DMEM supplemented with 10 % Fetal Bovine Serum and
124 1 % P/S at 95+% RH with 5 % CO₂ at 37 °C.

125 **2.2 Preparation of (Cur@NaCas)@CaP NPs**

126 Samples were prepared by rehydrating NaCas in 10 mM phosphate buffer solution
127 (pH 7.4) at room temperature (25 °C) with moderate stirring for 30 min to produce a
128 NaCas stock solution at 1 mg/mL. A Cur stock solution of 500 µg/mL in absolute
129 ethyl alcohol was prepared. 200 µL of the Cur stock solution was vigorously mixed at
130 600 rpm with 1 mL NaCas solution at room temperature for 2 h. The successfully
131 encapsulated Cur (Cur@NaCas) was separated from the non-encapsulated Cur by
132 centrifugation at 290 g for 10 min. The resultant supernatant containing the
133 Cur@NaCas was subjected to (i) secondary encapsulation, (ii) particle property
134 characterization or (iii) freeze-drying to produce Cur@NaCas NPs for further study.

135 Un-encapsulated Cur on the bottom was measured in order to calculate the drug
136 loading efficiency (DLE). Free curcumin was determined by UV-vis at 428 nm. The
137 DLE of Cur@NaCas was calculated according to following eq.(1):

$$138 \quad (1) \quad \text{DLE}(\%) = \frac{\text{total amount of added Cur} - \text{amount of Cur on the bottom}}{\text{total amount of added Cur}} \times 100\%$$

139 To facilitate the secondary encapsulation, 20 µL calcium chloride (CaCb) solution
140 (50 mM) was added to the Cur@NaCas NPs solution in PBS (10 mM, pH 7.4) to form
141 (Cur@NaCas)@CaP NPs. The mixture was mixed using a vortex mixer (SCIOLOGEX
142 MX-S) for 2 min and then allowed to stand for 24 h. The precipitate was either used
143 for immediate particle property characterization or it was freeze-dried to produce the

144 (Cur@NaCas)@CaP NPs powders that were used for further study. Un-encapsulated
145 Cur@NaCas on the supernatant was measured in order to calculate the DLE. The
146 DLE of (Cur@NaCas)@CaP was calculated according to following eq.(2).

$$147 \quad (2) \text{ DLE} = \frac{\text{total amount of added Cur@NaCas} - \text{amount of Cur@NaCas in supernatant}}{\text{total amount of added Cur@NaCas}} \times 100\%$$

148 **2.3 Characterization**

149 The various samples used and constructed in this study (NaCas, Cur@NaCas and
150 (Cur@NaCas)@CaP) were investigated using transmission emission microscopy
151 (TEM, Hitachi HT7700, Tokyo, Japan) and scanning electron microscope (SEM,
152 Hitachi S-4700, Tokyo, Japan).[35] The average size and zeta-potential of free Cur
153 and the various inclusion complexes were ascertained using dynamic light scattering
154 (DLS, Nano-ZS 2000, Malvern Instruments, UK). The crystalline characterization of
155 free Cur and the various inclusion complexes was facilitated using X-ray
156 diffractometer (XRD, D8 ADVANCE, Germany, Bruker) at a diffraction angle of 2 θ
157 ranging from 5 $^\circ$ to 50 $^\circ$ with a stepwise scan rate of 10 $^\circ$ /min at 0.2 $^\circ$ per step. The FT-
158 IR spectra of freeze-dried samples were obtained using a fourier-transform infrared
159 spectrometer (FT-IR, Nicolet 6700, Madison, WI, USA) with a scanning range of
160 4000 - 500 cm $^{-1}$. The fluorescence spectra for free Cur and encapsulated Cur were
161 recorded by employing a fluorescence spectrophotometer (Hitachi F7000, Tokyo,
162 Japan) at an excitation wavelength of 420 nm, with the emission spectra being
163 recorded of a range from 440 - 650 nm at a slit width of 5 nm. Dispersions of
164 inclusion complexes were prepared in deionized water. Free Cur was dissolved in
165 ethanol or deionized water to the same final concentration as in the encapsulated Cur.

166 **2.4 *In vitro* stability of nano-encapsulated Cur**

167 The *in vitro* stability of free Cur and the various NPs was determined according to a
168 previously reported method.[12] Following the various treatments, the samples were

169 centrifuged and the ethanolic supernatant was analyzed by HPLC(Liquid column: C₁₈
170 (200 mmx 4.6 mm, 5µm); Mobile phase: 0.1% phosphate - acetonitrile (50:50);
171 Detection wavelength: 430 nm; Velocity of flow: 1.0 ml/min ; 25°C; Injection volume:
172 20 µL). The initial data for all the cases was set as 100%.

173 **2.5 *In vitro* release of Cur**

174 The *in vitro* release of Cur from NaCas or NaCas@CaP NPs was established by a
175 dialysis protocol according to a method reported elsewhere.[36] First, Cur loaded
176 inclusion complex were fully dispersed in a release medium (PBS, pH 7.4 or pH 5.5)
177 in a dialysis bag (MWCO 3500Da), which was then put into a dissolution apparatus,
178 and immersed in 200 mL of the dissolution medium with 1 ¼(w/v) Tween-80 under
179 gentle stirring at a rate of 100 rpm at 37 °C. At various time intervals, an aliquot of
180 the sample was extracted and analyzed to determine the release of Cur by HPLC.

181 **2.6 Cellular Uptake Measured by Confocal Laser Scanning Microscope.**

182 A549 cells (4x10⁴ cells/well) were attached to a confocal laser dish over a 12 h
183 period, after which the cells were washed once with PBS and treated with either free
184 Cur or Cur-loaded NPs (2 mL, 5 µg/mL, in DMEM) and incubated at 37 °C, 5 % CO₂
185 for 6 h. Then the cells were washed twice with PBS to remove all extracellular Cur. A
186 4 % paraformaldehyde solution was added to fix the cells (at room temperature for 30
187 min), after which 200 µL PI was added to stain the cell nucleus for 15 min. Prior to
188 imaging , all the cells samples were washed once more with PBS. The images of
189 confocal laser scanning microscope (CLSM) were captured by exciting Cur at 442

190 run, PI at 488 run, with emissions measured at 475 run and 630 run respectively.

191 2.7 Cellular Antioxidant Activity

192 Cellular antioxidant activity (CAA) was determined according to the method
193 reported previously.[35] Briefly, MGC803 cells were seeded in 96-well plates with a
194 concentration of 2.5×10^5 cells per milliliter and incubated for 24 h. Then the growth
195 medium was removed and replaced with either 100 μ L fresh medium containing 2
196 μ g/mL free Cur or Cur-loaded NPs and incubated for another 24 h. After 24h, fresh
197 medium (100 μ L) containing 25 μ M DCFH-DA was added into each well and
198 incubated for 1 h. Then, all wells were rinsed with PBS before 100 μ L fresh medium
199 containing 600 μ M ABAP was added into each well. A microplate reader employing
200 an excitation wavelength of 485 nm and an emission wavelength of 535 nm was used
201 to measure the fluorescent intensity of samples, over an 1 h period at 5 minutes
202 intervals. The control samples were treated with DCFH-DA and ABAP only, while
203 the blank samples contained cells treated with DCFH-DA only. The area under the
204 time-fluorescence intensity curve can be obtained by integration, and the antioxidant
205 activity (CAA) units for natural antioxidant can be calculated using the following
206 eq.(3):

$$207 \quad (3) \text{ CAA} = 100 - \left(\frac{f_{SA}}{f_{CA}} \right) \times 100$$

208 f_{SA} represent the integral area of the fluorescence value-time curve by adding
209 different concentrations of Cur;

210 f_{CA} represent the integral area of the blank group fluorescence value-time curve.

211 **2.8 In Vitro Cell Anti - proliferation Assay.**

212 A549 cells were seeded into 96-well microtiter plates at a density of 4000 cells per
213 well in 100 μ L of medium. After 24 h, the cells were treated with a medium
214 containing DMSO-dissolved Cur, NaCas-encapsulated or NaCas@CaP-encapsulated
215 Cur. Other cells were untreated (negative controls) or treated only with DMSO,
216 NaCas or NaCas@CaP NPs at the concentrations as in the dispersions with
217 encapsulated curcumin (positive controls). After 72 h treatment, CCK-8 solution (20
218 μ L) was added to each well and then incubated for 1 h. The absorbance at 450 nm was
219 measured with a microplate reader (Bio-Tek Instruments, Winooski, VT). The
220 normalized cell viability was obtained after normalizing the viability of a treatment by
221 the viability of control cells treated with DMSO only. The cell viability can be
222 calculated using the following eq.(4):

$$223 \quad (4) \text{ Cell viability} = (A_{\text{treated}}/A_{\text{control}}) \times 100\%$$

224 where A_{treated} and A_{control} are the absorbance of the wells with cells treated by Cur and
225 the control, respectively. The mean and standard deviation from three-well replicates
226 were calculated.

227

228 **3. Results and discussion**


229 **3.1 Preparation and Characterization of CaP coated Core-Shell nanoparticles**

230 (Cur@NaCas)@CaP NPs were prepared using the self-assembly and surface-
231 coating method outlined above. By adjusting the concentration of NaCas and the
232 stirring speed during the encapsulation process, the optimized conditions were

233 determined as: 1 mg/mL NaCas (**Table S1**), 600 rpm/min (**Table S2**), 2h (**Table S3**),
234 achieving a DLE of 90.01 ± 1.29 %. See the supplementary data for more in-depth data
235 about the optimization of this methodology.

236 After that, calcium ions as CaCh were added which interacted with the phosphate
237 in PBS, which in turn allowed the formation of a CaP coating on the surface of NaCas
238 protein to obtain Cur@NaCas@CaP. The DLE of (Cur@NaCas)@CaP under
239 optimized conditions of CaP (**Table S4**) was 99.25 ± 1.97 %.

240 TEM was performed to identify the formation of core-shell structure, and the size
241 distribution of particles was determined by DLS (**Figure 1G**). The native NaCas
242 appeared as uniform and compact spherical structure (**Figure 1A**) with an average
243 size of 28 nm. The particle size of Cur@NaCas NPs was slightly larger than that of
244 native NaCas (**Figure 1B**) with an average size of 32 nm. After the application of a
245 $\text{Ca}_3(\text{PO}_4)_2$ coating, the formed particles in the range of 195-205 nm, with the TEM
246 image (**Figure 1C**) revealing a clear core-shell structure. The TEM image shows that
247 the core size of the hybrid NPs ranged from 80 to 120 nm, which is probably due to
248 the aggregation of Cur@NaCas. SEM also demonstrated the dimension change of
249 NPs and the results (**Figure 1D-F**) consistent with the TEM images.



250

251 **Figure 1.** Transmission electron microscopy (TEM) (A, B, and C) and scanning
 252 electron microscopy (D, E, and F) and particle size distribution of native NaCas (A,
 253 D, G), Cur@NaCas NPs (B, E, G) and (Cur@NaCas)@CaP NPs (C, F, G). G
 254 represent the particle size distribution of: native NaCas (black bars ranging from 22 to
 255 38 nm); Cur@NaCas (white bars ranging from 22 to 38 nm) the grey bars (24 to 36
 256 nm) represent the overlapping particle size distribution between native NaCas and
 257 Cur-in-NaCas ; and (Cur@NaCas)@CaP respectively (hatched bars ranging from 192
 258 to 208 nm). The blue boxed area in (C) shows a high magnification of this region by
 259 TEM.


260

261 The formation of the CaP shell was further evidenced by XRD. The XRD patterns

262 for free Cur (a), NaCas (b), Cur@NaCas NPs (c), (Cur@NaCas)@CaP NPs (d) and
263 NaCas@CaP NPs (e) are shown in **Figure 2A**. The powder diffraction pattern of Cur
264 displayed several sharp peaks at diffraction angles of 8, 8.9, 14.5, 17.2, 21.1,
265 suggesting that Cur existed in a crystalline form.[35, 37] Although NaCas was
266 amorphous lacking crystalline peaks (line 'b'), some minor evidence of crystalline
267 forms persisted in the Cur@NaCas NPs (line 'c'). The minor crystalline signals might
268 be due to fractions of the entrapped Cur protruding from the NaCas casing, which is
269 likely to be the result of the spontaneous encapsulation of free Cur by NaCas.
270 Furthermore, the characteristic peak of (Cur@NaCas)@CaP NPs and NaCas@CaP
271 NPs showed the same position with the complete absence of any diffraction peak
272 corresponding to Cur, indicating the formation of (Cur@NaCas)@CaP NPs where the
273 NaCas@CaP core-shell formation completely shielded the encapsulated Cur.

274 FT-IR spectroscopy was performed to verify the interaction between NPs and Cur,
275 and also to confirm the mechanisms of encapsulation and surface coating. The FT-IR
276 spectra of free Cur (a), NaCas (b), Cur@NaCas NPs (c), (Cur@NaCas)@CaP NPs (d)
277 and NaCas@CaP NPs (e) are shown in **Figure 2B**. Cur was characterized by discrete
278 absorption peaks at 3502 cm^{-1} (phenolic O-H stretching), 1720 cm^{-1} (C=O stretching
279 on the diketone groups), 1614 cm^{-1} and 1000 cm^{-1} (C=C bending on the aromatic
280 rings), 1515 cm^{-1} (C=C stretching in aromatic ring), 1450 cm^{-1} (C-H bending on
281 methyl groups), and 1300-1200 cm^{-1} (=C-O-CH₃ stretching of alkyl-aryl ether
282 groups). Most of the characteristic peak of Cur disappeared after encapsulation by
283 NaCas.[38] For NaCas, the characteristic peaks of at 3424 cm^{-1} (free O-H, N-H

284 absorbing), 1644 (amide I group) shifted to 3415 cm^{-1} , 1628 cm^{-1} respectively after
 285 self-assembling with Cur. These shifts are most likely due to the notion that hydrogen
 286 bonds of NaCas participated in the formation of Cur@NaCas NPs, which involved
 287 changes in the secondary structure of NaCas proteins.¹³⁹¹ Furthermore, the peaks of
 288 (Cur@NaCas)@CaP NPs at 1123 cm^{-1} , 1027 cm^{-1} , 599 cm^{-1} and 559 cm^{-1} remained
 289 the same as NaCas@CaP NPs, which appeared attributed to the antisymmetric
 290 stretching of PO_4 .^[40] These results indicate that $\text{Ca}_3(\text{PO}_4)_2$ molecules were attached
 291 to the surface of Cur@NaCas NPs by co-precipitation to form the external CaP shell.



292


293 **Figure 2.** (A) X-ray diffraction patterns and (B) Fourier-transform infrared spectra of
 294 the Cur (a), NaCas (b), Cur@NaCas NPs (c), (Cur@NaCas)@CaP NPs (d) and
 295 NaCas@CaP NPs (e).

296

297 Zeta-potential was also used to confirm the loading of Cur and the formation of
 298 core-shell structure (**Figure 3A**). The zeta-potential values of NaCas decreased from -
 299 22.1 to -32.5 after self-assembly with Cur, indicating an enhanced anionic surface
 300 coating on Cur@NaCas. When loading Cur in proteins, NaCas reassembled to lower

301 the number of less negatively charged K-casein and raise the number of high
302 negatively charged casein (as1-, as2-, -), which increased the overall magnitude of
303 the negative zeta-potential.[41] The zeta potential of CaP was -16.4 mV, which
304 represents the anionic nature of CaP. Following entrapment of Cur@CaNas by
305 $\text{Ca}_3(\text{PO}_4)_2$, the zeta-potential of NPs was marginally increased to -15.7 mV. This
306 confirmed that the shielding by a CaP layer on the surface of Cur@NaCas altered the
307 negative charge.[42] This higher zeta-potential of (Cur@NaCas)@CaP NPs would be
308 beneficial for its uptake into cells compared with NaCas NPs because of the lower
309 electrostatic repulsion, relative to the negatively charged surfaces of cancer cells,
310 which lowers the barrier to diffuse into cells.[43, 44] This hypothesis has been further
311 investigated in subsequent experiments.

312 Fluorescence spectrum was applied to study the intrinsic fluorescence of Cur as
313 the microenvironment changes in aqueous systems (**Figure 3B**). At an excitation
314 wavelength of 420 nm, Cur dissolved in ethanol showed the maximum light intensity
315 at 535 nm, while Cur dispersed in water almost without fluorescence. The blue shift
316 of Cur peak at 535 nm, to 517 nm after encapsulation of NaCas NPs, and the
317 fluorescence intensity increased at the same time. It explained that Cur was loaded
318 into the core of NaCas by hydrophobic interactions, which provided hydrophobic
319 regions for Cur.[45] After the CaP coating, the blue shift of Cur peak from 517 nm to
320 506.2 nm, and the further increased fluorescence intensity indicated that the surface of
321 NaCas was coated by CaP to form a more hydrophobic matrix.



322

323 **Figure 3.** (A) Average zeta-potential of NPs. (B) Fluorescence emission spectra of

324 Cur and NPs.

325 3.2 Thermal and UV Stability of (Cur@NaCas)@CaP

326 Thermal instability in aqueous solution is a major factor that limits Cur

327 bioavailability.[46] This can be further confirmed in our experiment (**Figure 4A**). The

328 rest of free Cur was 10.53 % after stored at 80 °C for 120 min, while 72.9 % of Cur

329 remaining at 25 °C. It was also found that NaCas encapsulation only limitedly

330 improved the thermal stability of Cur. After encapsulated with CaP coating, the

331 remaining Cur dramatically reached at 81.54 % under the same heating treatment.

332 Then, we studied the degradation kinetics of free and encapsulated Cur in aqueous

333 solution. Both free and NaCas encapsulated Cur displayed significantly faster

334 degradation at 80 °C than 25 °C (**Figure 4B and Figure SI**). After heated for 5 min at

335 80 °C, more than 60 % of free Cur was lost. However, more than 99 % of Cur loaded

336 in the NaCas@CaP NPs remained. When the heating time reached to 45 min, NaCas

337 loaded Cur showed about 50 % of loss. In contrast, about 90 % of the NaCas@CaP

338 loaded Cur remained. After heated for 120 min at 80 °C, the aqueous solution of free
339 and NaCas loaded Cur became transparent, and their colors faded (Seen the insert
340 photos in **Figure 4B**). As reported, about 50 % of soy protein isolate loaded Cur was
341 inactivated at 95 °C within 30 mins,[12] while the Cur encapsulated by NaCas@CaP
342 NPs didn't show sharp reduction within 2 h under high thermal condition. Thus, the
343 above results indicated that CaP surface coating could efficiently protect the guest
344 molecules from the thermal degradation.


345 Cur also easily degraded under UV-light.[47] Stored in the UV-light conditions
346 (**Figure 4C**), free Cur had a sharp degraded by about 81.75 % after storage of 30 min
347 and more than 90 % of free Cur degraded in 120 min. For NaCas NPs, almost 43 % of
348 loaded Cur degraded after 120 min. With CaP coating on the surface of NaCas, there
349 was a partial degradation by 12 % in 30 min, and then maintained a certainly stability.
350 Obviously, the shell of CaP provided a superior UV protection of at least 1.4 folds
351 than NaCas, and 8 folds better than free Cur.

352 **3.3 pH-Responsive Release Comparison of Cur from NaCas with or without CaP**

353 **Coating**

354 In practical applications the intend is not to retain the encapsulated compound
355 indefinitely. Instead, the intend would be to facilitate protection of the encapsulated
356 compounds prior to reaching its target, but then have a slow and regular release to
357 limit the rate of physical applications. In this work, the *in vitro* release experiments of
358 Cur@NaCas NPs and (Cur@NaCas)@CaP NPs in different PBS buffer (pH 7.4 and

359 5.5) were investigated and shown in **Figure 4D**. The whole release procedure lasted
360 12 h, and Tween 80 (1% w/v) was added to enhance the stability of Cur.[48] At both
361 7.4 and 5.5, more than 95 % of Cur loaded in NaCas NPs was released within 4 h.
362 Thus, a single protein carrier consisting of NaCas has the capability of facilitating a
363 pH-response release, however, the relative fast release could cause substantial drug
364 leakage and inactivation. Previous studies have shown that CaP is also a pH-sensitive
365 material.[31, 49] When encapsulated in a NaCas@CaP hybrid matrix, only 30 % of
366 Cur was released at 4 h in physiological pH (pH 7.4), while 66.9 % of Cur was
367 released after 12 h at pH 7.4. By contrast, the cumulative release of Cur reached to
368 99.8 % after 12 h at pH 5.5 (Figure 4D). Therefore, the pH-responsive release
369 behavior of NaCas@CaP NPs retards the premature drug release and subsequent rapid
370 degradation/deactivation of the drugs after administration, and achieves controlled
371 release around the acidic microenvironments of tumors sites.[48,50]




372

373 **Figure 4.** (A) In vitro stability of free Cur and Cur in the nanoparticles in water at pH
 374 7.4 upon storage in 120 min at 25 °C and 80 °C.(B) Degradation kinetics of free Cur
 375 and Cur in the NPs in water at 80 °C from up to 120 min , and the changes of free
 376 Cur(a and a') , Cur@NaCas (band b') and (Cur@NaCas)@CaP (c and c') before and
 377 after heating were shown in the picture.(C) Degradation kinetics of free Cur and Cur
 378 in the NPs under ultraviolet light at 25 °C.(D) Release profiles of Cur@NaCas NPs
 379 and (Cur@NaCas)@CaP NPs at PBS (pH 7.4 and 5.5) in 12 h.

380 3.4 Improved Cellular Uptake of NaCas@ CaP loaded Cur

381 Confocal laser scanning microscopy (CLSM) was used to investigate whether
 382 encapsulated compounds have improved cellular uptake capacity. The CLSM images
 383 through the A549 monolayer cells after incubation with DMSO, free Cur,

384 Cur@NaCas NPs, and (Cur@NaCas)@CaP NPs (all with equivalent concentration of
385 Cur) are shown in in **Figure 5**. The commercial fluorescent dye propidium iodide (PI)
386 was used to characterize cell morphology, and the fluorescence of Cur indicates the
387 cell uptake of NPs. (Cur@NaCas)@CaP NPs showed stronger green fluorescent
388 intensity than an equal concentration of free Cur and NaCas loaded Cur, suggesting
389 NaCas@CaP NPs can improve the cellular uptake ability of encapsulated
390 hydrophobic compounds. The reason for the lower green fluorescent intensity for the
391 Cur@NaCas NPs might be due to leakage of Cur from Cur@NaCas NPs. Free Cur
392 was shown to degrade rapidly and as such reduce its bioavailability at a slightly acidic
393 cancer cell environment pH (**Figure S2**). For the (Cur@NaCas)@CaP NPs, the
394 presence of a CaP shell increased the stability of Cur in a physiological aqueous
395 environment and reduced the cell uptake barriers between NPs and Cur (Figure 5),
396 thus evidencing improved cellular uptake and stability.[51 , 52] On the other hand, Cur
397 would be released from the NaCas core of the (Cur@NaCas)@CaP NPs following
398 cellular uptake. It is likely that any intracellular release would have been in part
399 facilitated by endosomes and lysosomes, and achieved a cumulative intracellular
400 release.[53] Thus, the synergistic effect of shell and core increased the cell uptake
401 capacity of NPs and achieved efficient intracellular release.




402

403 **Figure 5.** Uptake of free Cur and encapsulated Cur into epithelial cells (A549, human
 404 alveolar basal epithelial cells) as observed by confocal laser scanning microscopy
 405 (CLSM) after 4h of exposure. Column 'PI', Propidium iodide (PI)-only control;
 406 Column 'Cur', Cur-only control; Column 'PI + Cur', cells treated with both PI and
 407 Cur. (a) cells treated with DMSO; (b) cells treated with free Cur; (c) cells treated with
 408 Cur@NaCas NPs; and (d) cells treated with (Cur@NaCas)@CaP NPs

409 3.5 Cellular Antioxidant Activity

410 It has previously been shown that Cur has antioxidant activity and free radical
 411 scavenging activities.[47] The cellular anti-oxidant activity (CAA) of free Cur and
 412 encapsulated Cur were assessed by the MGC-803 cell model (**Figure 6A**), and the
 413 anti-proliferation activities of NPs on MGC-803 cells are shown in **Figure S3**.
 414 According to the principle of CAA, peroxy radicals produced by ABAP cause
 415 oxidation of DCFH to form the fluorescent DCF, the DCF fluorescence intensity
 416 reflects the degree of oxidation damage caused by free radicals.[35] The antioxidant

417 capacity of any natural compounds can be reflected by the reduced DCF fluorescence
 418 intensity. The results (Figure 6A) indicated that DCF accumulated continuously in
 419 the cells over time, while Cur could quench free radicals to reduce the concentration
 420 of intracellular DCF. The reduced accumulation of DCF demonstrates that both the
 421 added Cur@NaCas NPs and (Cur@NaCas)@CaP NPs have antioxidant activity,
 422 which is consistent with previous work that reported that Cur loaded inclusion
 423 complexes possessed a higher free radical scavenging capacity compared with free
 424 Cur.[54] The CAA value were determined using eq.(3). The CAA results indicate that
 425 the NaCas and NaCas@CaP NPs loaded Cur had better cellular anti-oxidant activity
 426 than free Cur (Figure 6B).



427

428 **Figure 6.** (A) The kinetics curve of DCF fluorescence from cellular anti-oxidant
 429 activity (CAA) of Cur, Cur@NaCas, (Cur@NaCas)@CaP, control, and blank sample.

430 In all instances the cells were exposed to equal amount of Cur. Error bars indicate the
431 standard deviation following triplicate determinations. (B)The comparison of cellular
432 anti-oxidant activity value for different samples. (C) Anti-proliferation activity the
433 blank NPs toxicity of human alveolar basal epithelial cells (A549 cells). (D) Anti-
434 proliferation activity of 1, 5, 10 and 20 $\mu\text{g}/\text{mL}$ DMSO-dissolved and encapsulated Cur
435 against A549 cells.

436 3.6 Cell Viability

437 In order to investigate the cytotoxicity of (Cur@NaCas)@CaP NPs in cancer cells,
438 we monitored the cell proliferation using human alveolar basal epithelial cancer cells
439 (A549 cells) as a model. The native NaCas and NaCas@CaP NPs (without Cur)
440 showed almost 100 % cell viability at 72 h (**Figure 6C**), indicating that the blank
441 nanoparticle was nontoxic and biocompatible with the cell model used in these
442 experiments.[55] However, with Cur encapsulated in either NaCas or NaCas@CaP
443 NPs showed an improved anti-proliferation activity against A549 cancer cells when
444 compared with free Cur (**Figure 6D**). When the concentration of free Cur was applied
445 at 1 $\mu\text{g}/\text{mL}$ and 5 $\mu\text{g}/\text{mL}$, it showed a mean cell viability of 92.6 % and 65.2 %
446 respectively; while the Cur@NaCas inclusion complex showed a mean cell viability
447 of 88.2 % and 56.6 % at 1 $\mu\text{g}/\text{mL}$ and 5 $\mu\text{g}/\text{mL}$ of free Cur equivalent respectively.
448 The (Cur@NaCas)@CaP inclusion complex did not show the same enhanced anti-
449 proliferation effect on A549 cells compared to free Cur at the same Cur concentration,
450 with a mean cell viability of 98.8 % and 77.0 % at 1 $\mu\text{g}/\text{mL}$ and 5 $\mu\text{g}/\text{mL}$ of free Cur

451 equivalent respectively. A more prominent improvement in the anti-proliferation
452 activity of NaCas@CaP loaded Cur was observed at an effective dose of free Cur 10
453 $\mu\text{g/mL}$, with a mean cell viability of 13.5 %. At the same effective Cur concentration,
454 the cell viability of free Cur and Cur@NaCas NPs was 51.7 % and 34.0 %. It appears
455 that the anticancer effect of NPs loaded with Cur was related to the release property
456 and biocompatibility of NPs, which is also relevant to the instability, insolubility and
457 concentration of Cur.[42, 56] More specifically, when considering Cur at a lower
458 concentration, the release rate of Cur from the NPs was less than the rate of
459 degradation, which resulted in a lower anti-cancer activity of the encapsulated Cur
460 compared to free Cur. At the higher concentration, free Cur gradually degraded in
461 aqueous conditions in which the experiments were carried out, due to Cur's instability
462 and low biocompatibility; This while the chemical stability of NPs loaded Cur at the
463 same equivalent concentrations was remarkably enhanced (Figure 6D). It appears that
464 the NaCas@CaP loaded Cur achieved a more continuous anti-cancer effect, which
465 agrees with the CLSM results in this research (Figure 5). At the highest concentration
466 tested (20 $\mu\text{g/mL}$) in this study, the cell viability of A549 cells exposed to both
467 Cur@NaCas loaded and (Cur@NaCas)@CaP loaded NPs was almost non-existent,
468 while the addition of an equivalent concentration of free Cur saw a viability of
469 approximately 30%. This could be ascribed to the degradation of free Cur under the
470 experimental conditions where some of the added free Cur might have already
471 degraded before its full weight of the higher concentration could affect the cells

472 (Figure S2), plus, it might have been possible that the higher concentration saturated
473 the anti-proliferation effect against A549 cancer cells.

474 **4. Conclusions**

475 In conclusion, a novel hybrid nanodelivery system was prepared using NaCas and
476 CaP. The nanosized NaCas@CaP NPs were shown to have an obvious core-shell
477 structure, which markedly improved the stability of Cur under thermal conditions and
478 UV light conditions. Besides, the pH-responsive release of Cur around cancer cell
479 environment was achieved. Furthermore, the results proved that NaCas@CaP NPs can
480 improve anti-oxidant activity, cell uptake ability and anti-proliferative activity of Cur
481 in living cells. Our research provided a simple and stable nano-platform for
482 encapsulating sensitive hydrophobic biomolecules. The results revealed that this core-
483 shell nanodelivery system was meaningful for keeping bioactivities of sensitive
484 molecules and improving the bioavailability in cancer treatment. Thus, this
485 nanodelivery system is expected to be applied for in food and pharmaceutical
486 products field.

487 For human health and practical application, further research is still undergoing in
488 our laboratory including the delivery behavior and uptake mechanism of this
489 nanodelivery system in various food and animals' systems, as well as the bioactivities
490 of encapsulated molecules after the delivery of gastrointestinal tract.

491

492 AUTHOR INFORMATION

493 Author Contributions

494 The first two authors have equal contributions

495 Notes

496 The authors declare no competing financial interest.

497 ACKNOWLEDGMENT

498 The authors acknowledged financial support from the National Natural Science
499 Foundation of China (21878014), the Double First-rate Program (ylkxj03), and the
500 111 Project (B13005).

501

502 REFERENCES

- 503 [1] X. Duan, H. Chen, L. Fan, J. Kong, Drug Self-Assembled Delivery System with
504 Dual Responsiveness for Cancer Chemotherapy, *ACS Biomater Sci Eng* 2(12) (2016)
505 2347-2354.
- 506 [2] Y. Li, Y. Wang, G. Huang, J. Gao, Cooperativity Principles in Self-Assembled
507 Nanomedicine, *Chem Rev* 118(11) (2018) 5359-5391.
- 508 [3] W. Cui, J. Li, G. Decher, Self-Assembled Smart Nanocarriers for Targeted Drug
509 Delivery, *Adv Mater* 28(6) (2016) 1302-11.
- 510 [4] M.H. Li, Z. Luo, Y.L. Zhao, Self-Assembled Hybrid Nanostructures: Versatile
511 Multifunctional Nanoplatforams for Cancer Diagnosis and Therapy, *Chem Mater* 30(1)
512 (2018) 25-53.
- 513 [5] L. Zhou, T. Qiu, F. Lv, L. Liu, J. Ying, S. Wang, Self-Assembled Nanomedicines
514 for Anticancer and Antibacterial Applications, *Adv Healthc Mater* 7(20) (2018)
515 e1800670.
- 516 [6] Y.M.a.H. Maeda, A New Concept for Macromolecular Therapeutics in Cancer
517 Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the
518 Antitumor Agent Smancsl, *Cancer Res* 46 (1986) 6387-6392.
- 519 [7] Y. Jin, R. Xin, P. Ai, D. Chen, Self-assembled drug delivery systems 2.
520 Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the
521 vesicle formation, *Int J Pharm* 350(1-2) (2008) 330-7.
- 522 [8] D. Kalyane, N. Raval, R. Maheshwari, V. Tambe, K. Kalia, R.K. Tekade,
523 Employment of enhanced permeability and retention effect (EPR): Nanoparticle-
524 based precision tools for targeting of therapeutic and diagnostic agent in cancer,
525 *Mater Sci Eng C* 98 (2019) 1252-1276.

- 526 [9] S.Y. Qin, A.Q. Zhang, S.X. Cheng, L. Rong, X.Z. Zhang, Drug self-delivery
527 systems for cancer therapy, *Biomaterials* 112 (2017) 234-247.
- 528 [10] S. Jaiswal, P. Mishra, Co-delivery of curcumin and serratiopeptidase in HeLa and
529 MCF-7 cells through nanoparticles show improved anti-cancer activity, *Mater Sci*
530 *Eng C* 92 (2018) 673-684.
- 531 [11] H. Lu, Q. Wang, G. Li, Y. Qiu, Q. Wei, Electrospun water-stable zein/ethyl
532 cellulose composite nanofiber and its drug release properties, *Mater Sci Eng C* 74
533 (2017) 86-93.
- 534 [12] F.P. Chen, B.S. Li, C.H. Tang, Nanocomplexation between curcumin and soy
535 protein isolate: influence on curcumin stability/bioaccessibility and in vitro protein
536 digestibility, *J Agric Food Chem* 63(13) (2015) 3559-69.
- 537 [13] W. Kajthunyakarn, D. Sakloetsakun, T. Pongjanyakul, Sodium caseinate-
538 magnesium aluminum silicate nanocomposite films for modified-release tablets,
539 *Mater Sci Eng C* 92 (2018) 827-839.
- 540 [14] R. Li, Y. Ma, Y. Dong, Z. Zhao, C. You, S. Huang, X. Li, F. Wang, Y. Zhang,
541 Novel Paclitaxel-Loaded Nanoparticles Based on Human H Chain Ferritin for Tumor-
542 Targeted Delivery, *ACS Biomater Sci Eng* 5 (2019) 6645-6654.
- 543 [15] K. Pan, H. Chen, S.J. Baek, Q. Zhong, Self-assembled curcumin-soluble soybean
544 polysaccharide nanoparticles: Physicochemical properties and in vitro anti-
545 proliferation activity against cancer cells, *Food Chem* 246 (2018) 82-89.
- 546 [16] Y. Zhang, Q.X. Zhong, Encapsulation of bixin in sodium caseinate to deliver the
547 colorant in transparent dispersions, *Food Hydrocoll* 33(1) (2013) 1-9.
- 548 [17] O. Menendez-Aguirre, A. Kessler, W. Stuetz, T. Grune, J. Weiss, J. Hinrichs,
549 Increased loading of vitamin D2 in reassembled casein micelles with temperature-
550 modulated high pressure treatment, *Food Res Int* 64 (2014) 74-80.
- 551 [18] R. Penalva, I. Esparza, M. Agueros, C.J. Gonzalez-Navarro, C. Gonzalez-
552 Ferrero, J.M. Irache, Casein nanoparticles as carriers for the oral delivery of folic
553 acid, *Food Hydrocoll* 44 (2015) 399-406.
- 554 [19] A. Rashidinejad, S.M. Loveday, G.B. Jameson, J.P. Hindmarsh, H. Singh, Rutin-
555 casein co-precipitates as potential delivery vehicles for flavonoid rutin, *Food*
556 *Hydrocoll* 96 (2019) 451-462.
- 557 [20] A. Bahri, M. Martin, C. Gergely, S. Marchesseau, D. Chevalier-Lucia,
558 Topographical and nanomechanical characterization of casein nanogel particles using
559 atomic force microscopy, *Food Hydrocoll* 83 (2018) 53-60.
- 560 [21] C. Moitzi, I. Portnaya, O. Glatter, O. Ramon, D. Danino, Effect of Temperature
561 on Self-Assembly of Bovine α -Casein above and below Isoelectric pH. Structural
562 Analysis by Cryogenic-Transmission Electron Microscopy and Small-Angle X-ray
563 Scattering, *Langmuir* 24(7) (2008) 3020-3029.
- 564 [22] M. Li, M.A.E. Auty, S.V. Crowley, A.L. Kelly, J.A. O'Mahony, A. Brodkorb,
565 Self-association of bovine α -casein as influenced by calcium chloride, buffer type and
566 temperature, *Food Hydrocoll* 88 (2019) 190-198.
- 567 [23] Y. Luo, K. Pan, Q. Zhong, Casein/pectin nanocomplexes as potential oral
568 delivery vehicles, *Int J Pharm* 486(1-2) (2015) 59-68.
- 569 [24] Q. Hu, M. Bae, E. Fleming, J.-Y. Lee, Y. Luo, Biocompatible polymeric

570 nanoparticles with exceptional gastrointestinal stability as oral delivery vehicles for
571 lipophilic bioactives, *Food Hydrocoll*, 89 (2019) 386-395..

572 [25] C. Sun, Y. Gao, Q. Zhong, Properties of Ternary Biopolymer Nanocomplexes of
573 Zein, Sodium Caseinate, and Propylene Glycol Alginate and Their Functions of
574 Stabilizing High Internal Phase Pickering Emulsions, *Langmuir* 34(31) (2018) 9215-
575 9227.

576 [26] H. Zhang, Y. Fu, Y. Xu, F. Niu, Z. Li, C. Ba, B. Jin, G. Chen, X. Li, One-step
577 assembly of zein/caseinate/alginate nanoparticles for encapsulation and improved
578 bioaccessibility of propolis, *Food Funct* 10(2) (2019) 635-645.

579 [27] M. Yerramilli, S. Ghosh, Long-term stability of sodium caseinate-stabilized
580 nanoemulsions, *J Food Sci Technol* 54(1) (2017) 82-92.

581 [28] Q. Hu, M. Bae, E. Fleming, J.-Y. Lee, Y. Luo, Biocompatible polymeric
582 nanoparticles with exceptional gastrointestinal stability as oral delivery vehicles for
583 lipophilic bioactives, *Food Hydrocoll* 89 (2019) 386-395.

584 [29] H.B. Yao, M.R. Gao, S.H. Yu, Small organic molecule templating synthesis of
585 organic-inorganic hybrid materials: their nanostructures and properties, *Nanoscale*
586 2(3) (2010) 323-34.

587 [30] E. Soo, S. Thakur, Z. Qu, S. Jambhrunkar, H.S. Parekh, A. Papat, Enhancing
588 delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach, *J*
589 *Colloid Interface Sci* 462 (2016) 368-74.

590 [31] P. Mi, D. Kokuryo, H. Cabral, H. Wu, Y. Terada, T. Saga, I. Aoki, N.
591 Nishiyama, K. Kataoka, A pH-activatable nanoparticle with signal-amplification
592 capabilities for non-invasive imaging of tumour malignancy, *Nat Nanotechnol* 11(8)
593 (2016) 724-30.

594 [32] F. Li, Q. Xing, Y. Han, Y. Li, W. Wang, T.S.H. Perera, H. Dai, Ultrasonically
595 assisted preparation of poly(acrylic acid)/calcium phosphate hybrid nanogels as pH-
596 responsive drug carriers, *Mater Sci Eng C* 80 (2017) 688-697.

597 [33] Q. Song, L. Li, K. Xiong, W. Tian, J. Lu, J. Wang, N. Huang, Q. Tu, Z. Yang, A
598 facile dopamine-mediated metal-catecholamine coating for therapeutic nitric oxide
599 gas interface-catalytic engineering of vascular devices, *Biomater Sci* 7(9) (2019)
600 3741-3750.

601 [34] M. Canillas, P. Pena, A.H. de Aza, M.A. Rodriguez, Calcium phosphates for
602 biomedical applications, *Boletin de la Sociedad Espanola de Ceramica y Vidrio* 56(3)
603 (2017) 91-112.

604 [35] Z. Liu, Q. Wu, J. He, F. Vriesekoop, H. Liang, Crystal-Seeded Growth of pH-
605 Responsive Metal-Organic Frameworks for Enhancing Encapsulation, Stability, and
606 Bioactivity of Hydrophobicity Compounds, *ACS Biomater Sci Eng* 5 (2019) 6581-
607 6589.

608 [36] A.F. Martins, P.V. Bueno, E.A. Almeida, F.H. Rodrigues, A.F. Rubira, E.C.
609 Muniz, Characterization of N-trimethyl chitosan/alginate complexes and curcumin
610 release, *Int J Biol Macromol* 57 (2013) 174-84.

611 [37] J. Wu, J. Wang, J. Zhang, Z. Zheng, D.L. Kaplan, G. Li, X. Wang, Oral Delivery
612 of Curcumin Using Silk Nano- and Microparticles, *ACS Biomater Sci Eng* 4(11)
613 (2018) 3885-3894.

614 [38] H. Xiang, D. Sun-Waterhouse, C. Cui, W. Wang, K. Dong, Modification of soy
615 protein isolate by glutaminase for nanocomplexation with curcumin, *Food Chem* 268
616 (2018) 504-512.

617 [39] H.Q. Chen, Q.X. Zhong, Processes improving the dispersibility of spray-dried
618 zein nanoparticles using sodium caseinate, *Food Hydrocoll* 35 (2014) 358-366.

619 [40] W.-H. Lee, C.-Y. Loo, R. Rohanizadeh, Functionalizing the surface of
620 hydroxyapatite drug carrier with carboxylic acid groups to modulate the loading and
621 release of curcumin nanoparticles, *Mater Sci Eng C* 99 (2019) 929-939.

622 [41] K. Pan, H. Chen, P.M. Davidson, Q. Zhong, Thymol nanoencapsulated by
623 sodium caseinate: physical and antilisterial properties, *J Agric Food Chem* 62(7)
624 (2014) 1649-57.

625 [42] B. Deng, M. Xia, J. Qian, R. Li, L. Li, J. Shen, G. Li, Y. Xie, Calcium
626 Phosphate-Reinforced Reduction-Sensitive Hyaluronic Acid Micelles for Delivering
627 Paclitaxel in Cancer Therapy, *Mol Pharm* 14(6) (2017) 1938-1949.

628 [43] A. Verma, F. Stellacci, Effect of Surface Properties on Nanoparticle-Cell
629 Interactions, *Small* 6(1) (2010) 12-21.

630 [44] Z. Zhou, Y. Shen, J. Tang, E. Jin, X. Ma, Q. Sun, B. Zhang, E.A. Van Kirk, W.J.
631 Murdoch, Linear polyethyleneimine-based charge-reversal nanoparticles for nuclear-
632 targeted drug delivery, *J Mater Chem* 21(47) (2011) 19114-19123.

633 [45] K. Pan, Q. Zhong, S.J. Baek, Enhanced dispersibility and bioactivity of curcumin
634 by encapsulation in casein nanocapsules, *J Agric Food Chem* 61(25) (2013) 6036-43.

635 [46] M. Kharat, Z. Du, G. Zhang, D.J. McClements, Physical and Chemical Stability
636 of Curcumin in Aqueous Solutions and Emulsions: Impact of pH, Temperature, and
637 Molecular Environment, *J Agric Food Chem* 65(8) (2017) 1525-1532.

638 [47] Z. Hussain, H.E. Thu, M.W. Amjad, F. Hussain, T.A. Ahmed, S. Khan,
639 Exploring recent developments to improve antioxidant, anti-inflammatory and
640 antimicrobial efficacy of curcumin: A review of new trends and future perspectives,
641 *Mater Sci Eng C* 77 (2017) 1316-1326.

642 [48] M. Zheng, S. Liu, X. Guan, Z. Xie, One-Step Synthesis of Nanoscale Zeolitic
643 Imidazolate Frameworks with High Curcumin Loading for Treatment of Cervical
644 Cancer, *ACS Appl Mater Interfaces* 7(40) (2015) 22181-7.

645 [49] P. Mi, N. Dewi, H. Yanagie, D. Kokuryo, M. Suzuki, Y. Sakurai, Y. Li, I. Aoki,
646 K. Ono, H. Takahashi, H. Cabral, N. Nishiyama, K. Kataoka, Hybrid Calcium
647 Phosphate-Polymeric Micelles Incorporating Gadolinium Chelates for Imaging-
648 Guided Gadolinium Neutron Capture Tumor Therapy, *ACS Nano* 9(6) (2015) 5913-
649 5921.

650 [50] L. Liu, J. Guo, P. Liu, Raspberry-Shaped Independent Temperature and pH Dual-
651 Responsive CPMAA@CPNIPAM Yolk/Shell Microspheres for Site-Specific
652 Targeted Delivery of Anticancer Drugs, *Ind Eng Chem Res* 55(16) (2016) 4790-4796.

653 [51] Y. Luo, Z. Teng, T.T. Wang, Q. Wang, Cellular uptake and transport of zein
654 nanoparticles: effects of sodium caseinate, *J Agric Food Chem* 61(31) (2013) 7621-9.

655 [52] P. Das, N.R. Jana, Length-Controlled Synthesis of Calcium Phosphate Nanorod
656 and Nanowire and Application in Intracellular Protein Delivery, *ACS Appl Mater*
657 *Interfaces* 8(13) (2016) 8710-20.

658 [53] S.J. Kaczmarczyk, K. Sitaraman, H.A. Young, S.H. Hughes, D.K. Chatterjee,
659 Protein delivery using engineered virus-like particles, *Proc Natl Acad Sci U S A*
660 108(41) (2011) 16998-7003.

661 [54] P. Jiang, J. Huang, C. Bao, L. Jiao, H. Zhao, Y. Du, F. Ren, Y. Li, Enzymatically
662 partial hydrolyzed α -lactalbumin peptides for self-assembled micelles formation and
663 their application for coencapsulation of multiple anti-oxidants, *J Agric Food Chem* 66
664 (2018) 12921-12930.

665 [55] W.H. Lee, C.Y. Loo, R. Rohanizadeh, Functionalizing the surface of
666 hydroxyapatite drug carrier with carboxylic acid groups to modulate the loading and
667 release of curcumin nanoparticles, *Mater Sci Eng C* 99 (2019) 929-939.

668 [56] B. Lei, M. Wang, Z. Jiang, W. Qi, R. Su, Z. He, Constructing Redox-Responsive
669 Metal-Organic Framework Nanocarriers for Anticancer Drug Delivery, *ACS Appl*
670 *Mater Interfaces* 10(19) (2018) 16698-16706.

Declaration of interests

D The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Author Statement

Hao Liang:

Conceptualization, methodology, resources, project administration, writing - original draft, writing - review & editing, supervision, funding acquisition

Qiao Wu:

Conceptualization, methodology, validation, formal analysis, investigation, data curation, writing - original draft

Huiling Gao

Conceptualization, methodology, supervision

Frank Vriesekoop

Formal analysis, writing - original draft, writing - review & editing

Zexun Liu

Methodology, resources.

Jie He

Methodology

Supporting Information

Calcium Phosphate Coated Core-Shell Protein Nanocarriers: Robust Stability, Controlled Release and Enhanced Anticancer Activity for Curcumin Delivery

Qiao Wu,^a Huiling Gao,^a Frank Vriesekoop,^c Zexun Liu,^a Jie He,^a Hao Liang^{*a, b}

^aState Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P.R. China

^bQinhuangdao Bohai Biological Research Institute of Beijing University of Chemical Technology, Qinhuangdao 066000, China

^cDepartment of Food Technology and Innovation, Harper Adams University, Newport TF10 8NB, Shropshire, United Kingdom.

Corresponding Author

* E-mail: lianghao@rmail.buct.edu.cn

Supplementary tables

Table S1 Effect of NaCas concentration on drug loading efficiency (DLE) (%).

NaCas (mg/mL)	Cur (mg/mL)	Stirring speed (rpm/min)	Stirring time (h)	DLE (%)
0.5	0.5	600	1.5	62.34±1.30
0.75	0.5	600	1.5	78.67±1.14
1	0.5	600	1.5	80.63±1.37
1.25	0.5	600	1.5	80.94±1.43
1.5	0.5	600	1.5	81.13±1.29

All samples were prepared at room temperature.

Table S2 Effect of stirring speed on DLE (%)

NaCas (mg/mL)	Cur (mg/mL)	Stirring speed (rpm/min)	Stirring time (h)	DLE (%)
1	0.5	400	1.5	57.83±1.17
1	0.5	500	1.5	63.49±1.23
1	0.5	600	1.5	80.98±1.27
1	0.5	700	1.5	84.24±1.31
1	0.5	800	1.5	84.32±1.43

All samples were prepared at room temperature.

Table S3 Effect of stirring time on DLE (%)

NaCas (mg/mL)	Cur (mg/mL)	Stirring speed (rpm/min)	Stirring time (h)	DLE (%)
1	0.5	700	0.5	50.64±1.34
1	0.5	700	1.0	73.68±1.49
1	0.5	700	1.5	84.97±1.38
1	0.5	700	2.0	90.01±1.29
1	0.5	700	2.5	90.27±1.44

All samples were prepared at room temperature.

Table S4 Effect of the added CaP volume on DLE (%)

CaP concentration (mM)	CaP volume (μ L)	Mixing time (min)	DLE (%)
50	5	2	21.57 \pm 2.06
50	10	2	53.24 \pm 1.92
50	15	2	80.42 \pm 2.14
50	20	2	99.25 \pm 1.97
50	25	2	99.47 \pm 2.03

All samples were prepared at room temperature.

Supplementary figures




Figure S1 Degradation kinetics of free Cur and Cur in the NPs in water from up to 120 min at 25 °C.




Figure S2 Degradation kinetics of free Cur at pH 5.5 PBS.




Figure S3 Anti-proliferation activity of 1, 2, 3, 4 and 5 µg/mL DMSO-dissolved and encapsulated Cur against MGC-803 cells, and treatment for 24 h.